GHK-Cu Before the Skin Studies: A Serum Tripeptide, Liver and Hepatoma Cell Cultures, and the Copper-Uptake Hypothesis (1973–1989)

RESEARCH · GHK-Cu · DISCOVERY AND CELL-CULTURE HISTORY

GHK-Cu Before the Skin Studies: A Serum Tripeptide, Liver and Hepatoma Cell Cultures, and the Copper-Uptake Hypothesis (1973–1989)

Most writing about GHK-Cu starts with skin and collagen. The laboratory literature starts somewhere else: with a factor in human serum that affected how long cultured liver cells survived. This overview follows that early line of work, from 1973 to 1989, through cell-culture and chemistry papers that shaped how the peptide is still described. It summarises published findings in cultured cells and test systems for laboratory readers. It is not guidance for human or veterinary use, and it makes no claims about any PurixLab product.

A serum factor and liver cells

In 1973, Pickart and Thaler reported a tripeptide in human serum that prolonged the survival of normal liver cells and stimulated growth in neoplastic liver [1]. A second 1973 paper described a synthetic tripeptide that increased survival of normal liver cells and stimulated growth in hepatoma cells [2]. By 1977 the serum factor had been identified as glycyl-histidyl-lysine, or GHK [3]. A caution: the PubMed records for these three papers carry no abstract, so we limit our statements about them to what their titles say.

Copper and iron turn up in the purification

A 1979 chromatography paper adds a practical detail. While isolating the tripeptide from human plasma, the authors found that copper and iron co-isolated with it. The metals interfered at several steps, including gel filtration and high-pressure silica-gel chromatography, and removing them with an insoluble chelating resin enhanced recovery of radiolabelled tripeptide from plasma 8-fold [4]. The authors suggested that removing transition metals may help when recovering peptides that are hard to isolate from biological sources [4]. For anyone measuring this peptide today, the lesson is that metal content affects recovery, a theme we examine in GHK-Cu as an Analytical Problem.

Peptide–metal complexes in hepatoma culture

A 1980 study in the Journal of Cellular Physiology tested the tripeptide with metals in a tumorigenic hepatoma line (HTC4). At physiological pH in vitro, the tripeptide associated with copper, cobalt, iron, molybdenum, manganese, nickel and zinc, but not with calcium, potassium or sodium. When growth was limited by lowering serum concentrations, the metals alone induced cell flattening and adhesion and inhibited DNA synthesis and lactic acid production. Nanomolar concentrations of the tripeptide neutralised those inhibitory effects and stimulated intercellular adhesion and growth, with copper and iron the most active metals [5]. The authors proposed that the peptide and metal form a complex before interacting with cells, and that this chelation might regulate biological activities influenced by transition metals [5].

The result matters methodologically. Under low-serum conditions, metal alone and metal with peptide behaved differently, so an experiment that omits either arm cannot separate them.

The copper-uptake hypothesis

The same year, a Nature paper pulled these strands together. The tripeptide co-isolated with approximately equimolar copper and about 1/5 molar iron, and maximal effects on HTC4 cells appeared when it was added with both metals. Several tripeptides with a histidyl-lysyl linkage were nearly as active. The authors noted a homology between the tripeptide and the copper transport sites on albumin and alpha-fetoprotein, where copper is bound to a histidyl residue next to a basic residue, and reported that the tripeptide forms complexes with copper(II) and enhances uptake of the metal into cultured hepatoma cells [6]. A 1981 review of culture applications concluded that present information suggested the tripeptide functions as a transporter of transition metals, in particular copper, to the cell surface for uptake. It reported activity across many cell types and organisms in culture, with an optimum between 10 and 200 ng/ml [7].

The albumin comparison was tested directly in 1981. Using equilibrium dialysis at pH 7.5, Lau and Sarkar found that the tripeptide competed with albumin for copper(II): at equimolar concentrations, about 42% of the copper was bound to the peptide. At the concentrations of copper, albumin, histidine and peptide judged physiologically relevant, about 6% of the copper was associated with low-molecular-weight components, and the authors discussed a possible role for these complexes in copper transport from blood to tissues [8]. Our earlier article on GHK-Cu and ageing research covers a separate question, the claims made about plasma levels.

An independent hepatoma study

Most early papers share an author group, so an independent test is useful. Barra studied Morris hepatoma 7777 cells and observed the greatest stimulation of thymidine and leucine incorporation at 2 ng/ml. In randomly proliferating cells, thymidine incorporation into DNA rose by 50% and leucine incorporation into protein by 29%. Effects were synergistic with insulin and glucagon, and cells in the G1 phase of the cell cycle were more sensitive. In serum-starved cells, thymidine incorporation increased earlier and peaked higher than in controls, which led the author to suggest that the tripeptide may help quiescent cells re-enter the cell cycle [9]. These are measurements in one cultured tumour line, not evidence about any whole organism.

A counterpoint: poor uptake in Ehrlich cells

Not every system fits the uptake hypothesis. In an electron spin resonance study, the copper complex formed no ESR-detectable adducts when added to glutathione or to Ehrlich ascites cells under the authors’ conditions. They described this as consistent with poor uptake of the complex by cells. They also found that a copper–tripeptide–histidine adduct was not stable in the presence of the cells, and argued that a copper–bis(histidine) complex forms as a consequence of the peptide interacting with cells [10]. The 1980 reports used hepatoma cells, this study used Ehrlich ascites cells, and the methods differ, so the abstracts do not resolve the discrepancy [6,10].

Design lessons for laboratory work

These are our reading of the papers, not findings from them:

  • Include metal-only and peptide-only arms. In low-serum hepatoma culture, metals alone and metals with the peptide produced opposite effects on DNA synthesis [5].
  • Record serum and medium. Responses depended on serum concentration, and the tripeptide co-purified with copper and iron from plasma, so serum lot and medium metal content are variables worth reporting [5,4].
  • Do not assume one cell type predicts another. Hepatoma and Ehrlich cell studies reported different pictures of copper handling [6,10].
  • State the exact material. The papers use GHL, GHK and the copper complex in turn, so name the form tested [7,10].

What remains open

  • Limited independence. Most papers above share authors, and several are decades old with methods that predate current analytical standards [4,5,6,10].
  • Missing abstracts. The 1973 and 1977 records are title-only in PubMed, so their detail is not summarised here [1,2,3].
  • Tumour-derived cells. Several systems are hepatoma lines, and the 1973 titles themselves separate survival of normal liver cells from growth of neoplastic ones [1,2].
  • Uptake mechanism. A transport role is proposed, and reported cell uptake differs between systems [6,7,10].
  • Concentration windows. Reported optima ranged from 2 ng/ml in one hepatoma line to 10–200 ng/ml in a general review [9,7].

Later work moved to gene-expression signatures, skin and matrix biology, which we cover in GHK-Cu and Gene Expression. The early cell-culture record is where the copper-binding and transport framing began.

GHK-Cu 50mg at PurixLab

GHK-Cu 50mg: a labelled lyophilized research vial with 50mg per vial, C$49 per vial (CAD, before tax), supplied for laboratory research only. It is not a cosmetic; our separate Copper Facial Mask is the finished cosmetic product. If your project needs particular supporting documentation, email [email protected] before ordering and tell us what you need. Product page: purixlab.com/product/ghk-cu-50mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View GHK-Cu 50mg

Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-7. PubMed 4349963
  2. Pickart L, Thayer L, Thaler MM. A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. Biochem Biophys Res Commun. 1973;54(2):562-6. PubMed 4356974 · doi:10.1016/0006-291x(73)91459-9
  3. Schlesinger DH, Pickart L, Thaler MM. Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia. 1977;33(3):324-5. PubMed 858356 · doi:10.1007/BF02002806
  4. Pickart L, Thaler MM, Millard M. Effect of transition metals on recovery from plasma of the growth-modulating tripeptide glycylhistidyllysine. J Chromatogr. 1979;175(1):65-73. PubMed 546910 · doi:10.1016/s0021-9673(00)86403-1
  5. Pickart L, Thaler MM. Growth-modulating tripeptide (glycylhistidyllysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol. 1980;102(2):129-39. PubMed 6246126 · doi:10.1002/jcp.1041020205
  6. Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-7. PubMed 7453802 · doi:10.1038/288715a0
  7. Pickart L. The use of glycylhistidyllysine in culture systems. In Vitro. 1981;17(6):459-66. PubMed 7021400 · doi:10.1007/BF02633506
  8. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981;199(3):649-56. PubMed 7340824 · PMC1163421 · doi:10.1042/bj1990649
  9. Barra R. Effects of glycyl-histidyl-lysine on Morris hepatoma 7777 cells. Cytobios. 1987;52(209):99-107. PubMed 3319436
  10. Antholine WE, Petering DH, Pickart L. ESR studies of the interaction of copper(II)GHK, histidine, and Ehrlich cells. J Inorg Biochem. 1989;35(3):215-24. PubMed 2542448 · doi:10.1016/0162-0134(89)84011-5

Leave a Comment

Your email address will not be published. Required fields are marked *